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IMPORTANCE International literature has shown that teledermoscopy referral may be
a viable method for skin cancer referral; however, no economic investigations have occurred
in Australia.
OBJECTIVE To assess the cost-effectiveness of teledermoscopy as a referral mechanism for
skin cancer diagnosis andmanagement in Australia.
DESIGN, SETTING, AND PARTICIPANTS Cost-effectiveness analysis using a decision-analytic
model of Australian primary care, informed by publicly available data.
INTERVENTIONS We compared the costs of teledermoscopy referral (electronic referral
containing digital dermoscopic images) vs usual care (a written referral letter) for specialist
dermatologist review of a suspected skin cancer.
MAIN OUTCOMES ANDMEASURES Cost and time in days to clinical resolution, where clinical
resolution was defined as diagnosis by a dermatologist or excision by a general practitioner.
Probabilistic sensitivity analysis was performed to examine the uncertainty of the
main results.
RESULTS Findings from the decision-analytic model showed that themean time to clinical
resolution was 9 days (range, 1-50 days) with teledermoscopy referral compared with 35 days
(range, 0-138 days) with usual care alone (difference, 26 days; 95% credible interval [CrI],
13-38 days). The estimatedmean cost difference between teledermoscopy referral
(A$318.39) vs usual care (A$263.75) was A$54.64 (95% CrI, A$22.69-A$97.35) per person.
The incremental cost per day saved to clinical resolution was A$2.10 (95% CrI,
A$0.87-A$5.29).
CONCLUSIONS AND RELEVANCE Using teledermoscopy for skin cancer referral and triage in
Australia would cost A$54.64 extra per case on average but would result in clinical resolution
26 days sooner than usual care. Implementation recommendations depend on the
preferences of the Australian health system decisionmakers for either lower cost or
expedited clinical resolution. Further research around the clinical significance of expedited
clinical resolution and its importance for patients could inform implementation
recommendations for the Australian setting.
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S kin cancer presents a global health challenge. InAustralia, melanoma accounts formore than 10% of alldiagnosed and reported cancers, with an estimated
13 280 new cases diagnosed in 2016.1 The incidence of mela-
noma is increasing. Keratinocyte skin cancers (squamous
and basal cell carcinomas) and other skin cancers are not
nationally reported and occur between 10 and 20 timesmore
often than melanoma.1
Teledermatology is the provision of dermatologic care at a
distance using information and communications technology.
Teledermatologyoftenusesstore-and-forwardcommunication,
inwhichdigital imagesofaskin lesionarecaptured, typically in
primary care, and subsequently forwarded to a dermatologist
along with clinical information for review or management
advice. In addition to the provision of virtual consultations,
teledermatologycanalsobeusedto facilitate the triageof refer-
rals for specialist care.2-5When comparedwith awritten refer-
ral forspecialistcare,thevisual informationincludedinateleder-
matology referral provides extra information to assist with
appropriate triage and patientmanagement. Teledermatology
referrals can result in earlier assessment and treatment6 and in
reducedwaiting times andwaiting lists.7When clinically indi-
cated, somepatients donotneed tobe seenbyadermatologist
and insteadcanbemanagedbytheirgeneralpractitioners (GPs)
often under advice from a dermatologist.8-10
Dermoscopyisanoninvasivediagnostictechniquethat links
clinical dermatologyanddermatopathologyofpigmentedand
nonpigmentedskin lesionsbyenablingthevisualizationofmor-
phological features not seen by the naked eye.11 Teledermos-
copy is a formof teledermatology that specifically involves the
store-and-forwarding of digital dermoscopic images. When
compared with other imaging techniques, teledermoscopy
improves diagnostic accuracy.12,13 Teledermoscopy is not cur-
rently reimbursedunderMedicare (Australia’suniversalhealth
scheme funded by the federal government).
At present, there are no published economic evaluations
for teledermoscopy services specific to the Australian health
caresystem,andthereare fewinternational studiesavailable.14
The implementation of newmodels of care requires informa-
tion on their comparative cost-effectiveness. Therefore, the
purpose of this study was to examine the cost-effectiveness
of teledermoscopy as a referralmechanism for skin cancer di-
agnosis inAustralia anddetermine its value for improving the
management of skin cancer.
Methods
Overview
An ethics waiver was granted by the University of Queens-
land Human Ethics Research Office because the study used
only previously collected, deidentified data. The cost-
effectiveness of teledermoscopy referral for a suspected skin
cancer was compared with usual care using a decision-
analytic model. A teledermoscopy referral is an electronic
referral to adermatologist containingdigital dermoscopic im-
ages and clinical information, whereas usual care is a written
referral from a GP containing clinical information only.
Thedecision-analyticmodelwasdeveloped inTreeAgePro
software, release 2.1 (2016). The model represented path-
waysof clinicalmanagementof suspectedskincancer inagen-
eral adult population. The model has 2 arms, 1 representing
usual care for suspected skin cancer in Australia and 1 repre-
senting the teledermoscopy referral intervention (Figure 1).
Themodel endpointwas clinical resolution, defined asdi-
agnosis by a dermatologist or excision of lesion by a GP. Diag-
nostic outcomes were melanoma, keratinocyte skin cancer
(squamous cell carcinoma or basal cell carcinoma), and be-
nign neoplasms (clinically and dermoscopically mimicking
melanoma or a keratinocyte skin cancer). Costs were esti-
mated from the perspective of the Australian Common-
wealth Government (administrators of the Medical Benefits
Scheme [MBS]), and included the costs of consultation,
excision, and histopathologic analysis. Histopathologic con-
firmation of excised lesions is required before claiming items
on the MBS to ensure correct itemization and payment for
health care professionals.15
Comparative Treatments
InAustralia, usual care for a patient beginswith a visit to aGP.
Suspicious skin lesions may be detected during routine skin
checks or opportunistically when patients visit their GP for a
differentpurpose.Afterexamining theareaof concernandper-
forming a full skin check, the GP can perform a biopsy or ex-
cision for histopathologic analysis or refer thepatient to ader-
matologist formanagement. If referral is selected, theGPwill
write a referral letter and forward it to a nominated derma-
tologist or to the patient, who can submit to a dermatologist
of their choice. When the patient has a consultation with the
dermatologist, thedermatologistwill undertake a full skin ex-
amination with or without a dermoscope, take dermoscopic
images where appropriate, and if necessary perform a biopsy
or excision. This process may occur across single or multiple
visits with either the GP and/or dermatologist.
For teledermoscopy referral, rather than writing refer-
rals, the GP captures and sends a teledermoscopy imagewith
clinical notes to any participating dermatologist. Once re-
viewed by a dermatologist, the teledermoscopy information
could either be used to advise the GP ofmanagement options
(eg, to excise or monitor), or if necessary, schedule the
patient for an in-person dermatologist consultation.
Key Points
Question Is teledermoscopy cost-effective for skin cancer referral
and triage in Australia?
Findings In this decision-analytic modeling study using
deidentified Australian health system data, store-and-forward
teledermoscopy skin cancer referral was estimated to cost
A$54.64 per personmore than usual care but enabled clinical
resolution to be achieved amean of 26 days earlier. The
incremental cost per day saved to clinical resolution was A$2.10.
Meaning Incorporating teledermoscopy as a referral method for
skin cancer in Australia has the potential to benefit patients by
providing earlier clinical resolution at additional cost to Medicare.
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Model Inputs
Data estimates that informed themodelwere sourced system-
aticallyfromliteraturesearchesandgovernmentdatabases.Prob-
abilitydataweresourcedfrominternationalpublicationsthathad
performedstudieswith similarusual care and teledermoscopy
referral intervention(Table1).TheAustralianBetteringtheEvalu-
ationandCareofHealth (BEACH)report informedtreatmentes-
timates forproportionofoccasionswhenGPschosemonitoring
(noactive treatment) for suspicious lesions,or rateof referral to
adermatologist (Table 1).17 TheBEACHprogramrunsoutof the
Universityof Sydneyandcollectsdata about the clinical activi-
ties of Australian GPs. Discounting of costs and benefits to the
presentdaywasnotrelevanttotheseanalysesduetothe4-month
time horizon.
Cost data to inform themodelwere sourced from theAus-
tralian Department of Health MBS (Table 1). The dermatolo-
gist teledermoscopy consult fee was set to be the same as the
dermatologist in-person consultation fee, A$72.75, aligning
with theMedical Services Advisory Committee for asynchro-
nous store-and-forward reimbursement.16 Costs for excision
of melanoma, keratinocyte skin cancer, and benign neo-
plasmwere informed by relevantMBS item codes (Table 1).22
Because there are multiple MBS item codes for each type of
skin lesion, a single price per lesion typewas calculated using
a weighted average. Average weighted costs were calculated
using MBS data from March 2013 to April 2014; this time-
frame was selected to align with the BEACH report.15,17
The measure of benefit for this analysis was days to
clinical resolution. Clinical resolution was defined as diagno-
sis by a dermatologist, or excision and histopathologic analy-
sis by a GP. The time in days between a GP consultation and
excision of a suspected skin cancer was set to 1 day and is the
same inbotharmsof themodel.All other time informationwas
taken from a prospective cohort study performed in New
Zealand with 300 participants in 2012.8 This study was se-
lectedbecauseof the comparability of theNewZealandhealth
system and skin cancer risk to Australia; existing alternatives
were cohort studies from Spain or the United States.4,23
Analyses
The model performed an expected-values analysis by aggre-
gating the probabilities and costs in the pathways to calculate
the mean cost per person. The incremental cost-effective-
ness ratiowas calculatedbydividing thedifference in costs of
the 2 options by the difference in days to clinical resolution
(benefit). Cost inputs were in 2016 Australian dollars.
One-way sensitivity analysis was performed by sepa-
rately varying allmodel inputswithinplausible ranges of high
and low values (from relevant sources or imputed (Table 1).
Alternative probabilities were extracted from the published
studies (Table 1). Frequencies of physician visits and pathol-
ogy testingvariedbetween 1 and3visits or tests,which in turn
affected service costs (Table 1).
Probabilistic sensitivity analysis was undertaken by re-
sampling the cost andprobabilities (concurrently)withinpre-
specifieddistributions (Table 1). Cost estimates andprobabili-
ties were randomly resampled according to γ and β
distributions, respectively (Table 1).One thousandMonteCarlo
simulationswere run, resulting ina rangeofplausible costsand
effects. These simulation data allowed for the estimation of a
95%credible interval (CrI) formodel results to address theun-
certainty in themodel inputs. EachCrIwas estimated by rank
Figure 1. Decision-Analytic Model Structure
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ordering the results sequentially and excluding the highest
2.5% and lowest 2.5% of values.
Results
Teledermoscopy referral had amean cost of A$318.39 per case
and took amean of 9 days (range, 1-50 days) to clinical resolu-
tion,while usual care cost A$263.75with 35 days (range, 0-138
days) toclinical resolution(Table2).Therefore, teledermoscopy
referral costA$54.64 (95%CrI,A$22.69-A$97.35)morepercase
thanusual care alone andwas associatedwith amean reduced
Table 1. Cost and Probability Estimates
Variable
Model
Estimate
Sensitivity Values Distribution
Parameters SourceMinimum Maximum
Costs, A$
GP consultation fee 37.05 37.05 (1 consult) 111.15 (3 consults) α = 6.10, λ = 0.16 MBS item 2315
Dermatologist consultation fee 72.75 72.75 (1 consult) 145.50 (2 consults) α = 23.52, λ = 0.32 MBS item 10415
Dermatologist
teledermatology consult
72.75 36.38 (50%) 109.12 (150%) α = 23.52, λ = 0.32 MSAC Application (refers to
MBS item 104)15,16
Histopathologic analysis 107.12 107.12
(1 instance)
214.24
(2 instances)
α = 28.69, λ = 0.27 Weighted average of MBS items
72816-72818 and 7283015
Benign neoplasm excision 91.72 76.40
(lowest MBS cost)
126.05
(highest MBS cost)
α = 84.13, λ = 0.92 Weighted average of MBS items
31200-3121015
Keratinocyte skin cancer excision 157.36 155.85
(lowest MBS cost)
299.25
(highest MBS cost)
α = 39.62, λ = 0.25 Weighted average of MBS items
31255-3129015
Melanoma skin cancer excision 250.92 278.65
(lowest MBS cost)
369.00
(highest MBS cost)
α = 279.83, λ = 1.12 Weighted average of MBS items
31300-3133515
Any skin cancer excision
(keratinocyte or melanoma
skin cancer)
161.08 155.85
(lowest MBS cost)
369.00
(highest MBS cost)
α = 21.18, λ = 0.13 Weighted average of MBS items
31200-31210, 31255-31290,
and 31300-3133515
Probabilities
GP refer to dermatologist
(usual care)
0.31 0.19 0.31 α = 165.46, β = 368.29 BEACH Report 2013-201417
GP management condition
without referral (usual care)
0.7 0.4 0.7 α = 9.51, β = 4.08 BEACH Report 2013-20149
GP refer to dermatologist
via teledermatology
0.64 0.15 0.85 α = 9.60, β = 5.40 Morton et al,18 2011
Postteledermatology patient return
to GP for management
0.7 0.4 0.7 α = 58.10, β = 24.90 Snoswell et al,14 2016
Postteledermatology patient
attend in-person appointment
with dermatologist
0.2879 0.02 0.8 α = 3.20, β = 7.93 Moreno-Ramirez et al,4 2007
GP excise melanoma skin cancer 0.03 0.01 0.09 α = 34.89, β = 1128.11 English et al,19 2004
GP excise keratinocyte skin cancer 0.67 0.19 0.96 α = 8.10, β = 3.99 English et al,19 2004
Dermatologist in-person excise
melanoma skin cancer
0.112 0.088 0.173 α = 56.72, β = 449.71 Taylor et al,20 2012
Dermatologist in-person excise
keratinocyte skin cancer
0.247 0.1 0.8 α = 18.13, β = 55.27 Taylor et al,20 2012
Postteledermatology GP consult
and no action
0.2 0.2 0.8 α = 12.60, β = 50.4 Massone et al,21 2014
Postteledermatology GP consult
and excise melanoma skin cancer
0.01 0.01 0.09 α = 3.95, β = 391.05 Massone et al,21 2014
Postteledermatology GP consult
and excise keratinocyte skin cancer
0.22 0.2 0.96 α = 14.88, β = 52.76 Massone et al,21 2014
Outcomes, Time, d
GP consult to GP excision
without referral
1 0 1 No distribution Same on both arms,
therefore set to 1
GP consult to final resolution
(excision or dermatologist
appointment) in usual care
114 61 138 No distribution Lim et al,8,14 2012
GP consult to final resolution
(excision or dermatologist
appointment) via teledermatology
39 13 50 No distribution Lim et al,8,14 2012
GP teledermatology referral
to GP no action
2 1 7 No distribution Lim et al,8,14 2012
Abbreviations: BEACH,Bettering theEvaluation andCareofHealth;GP, general practitioner;MBS,Medical Benefits Scheme;MSAC,Medical ServicesAdvisoryCommittee.
Table 2. Incremental Cost-effectiveness Analysis
Group Mean Cost, A$
Mean Time
to Clinical
Resolution, d
Usual care 263.75 35
Usual care with
teledermoscopy
318.39 9
Difference (95% CrI) 54.64
(22.69-97.35)
26 (13-38)
Incremental
cost-effectiveness ratio per day
saved to clinical resolution
(95% CrI)
2.10
(0.87-5.29)
Abbreviation: CrI, credible interval.
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timetoclinicalresolutionof26(95%CrI,13-38)days.Thisresulted
in an incremental cost-effectiveness ratio of A$2.10 (95% CrI,
A$0.87-A$5.29) per day saved to clinical resolution (Table 2).
In 1-waysensitivityanalyses, themost influential cost com-
ponentswere pathology testing (range of 1-2 tests), GP consul-
tation fee (rangeof 1-3appointments), andteledermoscopyder-
matologist consultation fee (range of 50%-150%) (Figure 2).
Influentialprobability componentswere theprobabilityof aGP
referring their patients via teledermoscopy, and the probabil-
ity that after a teledermoscopy consultation the dermatologist
would instruct the patient to return to their referring practi-
tioner for diagnosis or treatment. As the number referred back
to their GP decreased from 90% to 10%, the incremental cost-
effectiveness ratio changed from A$1.55 to A$6.23 per day to
clinical resolution. This was to be expected because the cost-
effectiveness of teledermoscopy after implementation would
dependontheuptakeof referralsusing teledermoscopybyGPs
and the number of in-person dermatologist appointments
avoided.
Results from the probabilistic sensitivity analyses showed
costs ranging fromA$22.69 toA$97.35perperson, and for time
toclinicalresolutionfrom13to38days.Thisvariationinestimates
meant that theoverall incremental cost-effectiveness ratiowas
estimatedbetweenA$0.87andA$5.29perday saved to resolu-
tion(Table2).Figure3showsaclearseparationbetweenthecost-
effectiveness ratiosof teledermoscopyandusual care; teleder-
moscopy had a higher cost with faster clinical resolution than
usual carewithin themodeled conditions.
Discussion
Teledermoscopy referral has the potential to increase the effi-
ciency of a dermoscopic case of care, reduce the rate of unnec-
essary biopsies, and reduce inappropriate referral for special-
ist consultations. To our knowledge, this is the first study to
evaluatetheeconomic impactof teledermoscopyreferral for the
management of suspected skin cancers in the Australian con-
text. Under themodeled conditions, it was found that teleder-
moscopy referralwouldonaverage cost an additionalA$54.64
per case compared with usual care but would reduce time to
clinical resolutionby26days.Althoughusing teledermoscopy
referral can increase the overall cost of treatment, the extra
A$54.64percasemaybea justifiablecost for theAustraliangov-
ernment for expedited diagnosis and treatment.
Consistent with our findings, studies in other countries
have demonstrated that teledermoscopy services were
of comparable or higher cost vs usual care with positive
benefits.10,14,24-26 Internationally, teledermoscopy referral
systems have been successfully piloted with benefits similar
to thosedemonstratedbythismodel.8-10Thesestudies showed
that when used as a referral method, teledermoscopy meant
that 39% to 88% of patients did not have to attend an in-
person consultationwith their dermatologist andwere able to
Figure 2. One-way Sensitivity Analysis forModel Inputs Expressed in Incremental Cost-effectiveness Ratio Values
(Cost per Days to Clinical Resolution)
1 2 3 4 5 6
Probability that after teledermatology the patient
be referred back to GP for management
Time (d) from GP visit to final resolution (excision
or dermatologist appointment) in usual care
Probability that a dermatologist face-to-face
consultation will result in a melanoma excision
Probability that GP will refer to dermatologist
via teledermatology
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0 7
Incremental Cost-effectiveness Ratio
Output for a 1-way sensitivity analysis expressed as an incremental cost-effectiveness ratio in the form of a tornado diagram. GP indicates general practitioner.
The dashed line at $2.10 indicates themean incremental per day saved to clinical resolution.
Figure 3. Probabilistic Sensitivity Analysis Simulation
for Cost-effectiveness (Cost per Days to Clinical Resolution)
0
0 50 60
500
400
Co
st
, $
 A
us
tr
al
ia
n
Effectiveness, d
300
200
100
20 30 4010
Conventional care 
Conventional care + teledermoscopy
Scatterplot output from the probabilistic sensitivity analysis simulation
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teledermoscopy care.
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bemanagedby their GP.14,26 Eachpatient referred to aderma-
tologist for a teledermoscopy consultation that resulted inGP
management (rather than requiring an in-person dermatolo-
gist consultation) increased the cost-effectiveness of tele-
dermoscopy referral because dermatologists attract a higher
attendance fee than GPs (Figure 2). In addition, accurate der-
matologist diagnosis via teledermoscopy has the potential to
avoid erroneously excising benignneoplasms, preventing ex-
cision andhistopathology costs. Teledermoscopy referral can
optimize triage for in-persondermatologist appointments,due
to the visual information about the condition,10,24,25 thereby
ensuring thatdermatologist appointments are available forur-
gent cases when required.14
In Australia, the government routinely reimburses real-
time telehealth services (eg, video consultations) at a higher
rate than in-personservices.Thismeasure is to incentivize tele-
healthuseandoccursbecausepractitionersareentitledtoclaim
their standardattendance feeplus a telehealth itemfee,which
is generally equal to 50% of their attendance fees. The Aus-
tralasian College of Dermatologists’ application to the Com-
monwealth’s Department of Health to fund teledermoscopy
under Medicare proposed an equal reimbursement for store-
and-forward teledermatology comparedwith in-person care;
however, the application was not endorsed by the Medical
Services Advisory Committee.16 Reducing the consultation
fee for teledermoscopy (modeled in this study as equal to the
in-persondermatologist reimbursement fee) increases thecost-
effectiveness of the teledermoscopy service.
To effectively implement teledermoscopy services at the
substitution rates that achieve desirable cost-effectiveness, a
streamlined dermoscopic image capture process for general
practice would be essential.7,27 Capturing dermoscopic im-
ages andcompleting adigital referral formcould increase gen-
eral practice appointment time by as much as 11:32 minutes
(range, 7:02-26:44 minutes)28; this may serve as a disincen-
tive toGPs in theAustralian fee-for-servicemodel. Using sup-
port staff could reduce this barrier to implementation: once
the GP has identified the lesions of interest, they could cap-
ture the images and complete some of the digital referral.7,26
Further research around the clinical significance of expe-
dited clinical resolution and its importance for patients could
inform implementation recommendations for the Australian
setting. The same goes for research into what consumers are
willing to pay for teledermoscopy given its ability to reduce
the time to clinical resolution. If teledermoscopy remains
unfundedby the government, thenpatientsmaybewilling to
self-fund the service in aprivate capacity to reduce their travel
and receive a faster specialist opinion.
Limitations
The model examined costs from the perspective of the Aus-
tralian Commonwealth Government in community outpa-
tient settings. The results are therefore only applicable to the
Australian health care setting. Thismodel was not applicable
to patients treated through alternate clinical pathways, in-
cluding those who receive inpatient treatment in a hospital.
Due to limited data regarding teledermoscopy in Australia,
probability data were sourced from select international clini-
cal trials that demonstrated similar clinical pathways to Aus-
tralia. Due to the comparatively high rate of skin cancer in
Australia, theuseof international probabilitydatamayunder-
estimate skin cancer incidence and the impact of teledermos-
copy. Sensitivity analysis was used to examine the impact of
variations inprobabilities. Themodel doesnotdistinguishbe-
tween GPs who are working in GP clinics and those working
in skin cancer clinics; referral and excision rates for the later
may vary from those presented.29
Althoughfewpreviouseconomicmodelshaveexaminedthe
cost-effectivenessofteledermoscopyserviceprovision,thereare
several randomized clinical trials and observational trials that
havecollectedcost informationalongsidetheirclinicaldata.14,30
One strength of this study is that actual cost datawere used to
informourmodel for all items except the teledermoscopy fee.
Several costswere excluded from themodel, for example,
those associated with hospital treatments or referrals man-
aged in a hospital, biopsies, and the costs incurred by patients
(co-payments and other out-of-pocket expenses). Patient-
incurredcosts are likely tobe substantial forpatientswhoneed
to travel from rural areas to access metropolitan dermatolo-
gists in theusual care scenario.Australiahas travel subsidyand
reimbursementschemes foreligiblepatients;however, theyare
onlyavailabletopatients inthepublichospitalsystem,notthose
accessing care throughcommunity-basedmedical practices as
described in this model. Therefore, if teledermoscopy as de-
scribed in this model was examined from a societal perspec-
tive, it would likely have superior cost-effectiveness to
usual care.
Notexcisingbenignlesionsthatwouldotherwiseberemoved
maybeanoptimaloutcome for teledermoscopy.Thechange in
excisionrates forbenignneoplasmasameasureofeffectiveness
assumes that optimal clinical resolutionwould be to leave be-
nignneoplasms intact.However,patientsoften requestbenign
lesions be excised for cosmetic, discomfort, or other reasons;
therefore, the costs for benign lesion excision may have been
underestimated.31,32
Time in days to clinical resolution was taken from a
NewZealandstudyas thebest available source.This is relevant
to the Australian context becauseNewZealand also has a high
incidence of skin cancers and a similar health system to the
Australia.18Theuseof internationalvaluesmayhavethepoten-
tialtounderestimateoroverestimatethetimecomponentsinthis
model.However, theNewZealandvaluesused topopulate the
model fallwithin the rangeof time indays toclinical resolution
shownbyother internationalstudies.Theseotherstudiesexam-
iningteledermoscopyreferral reported13to50dayswhenusing
teledermoscopy referral, and61 to 138days forusual care.8-10,33
Conclusions
Teledermoscopy for skin cancer referral and triage inAustralia
will increase the cost per case but reduce time to clinical reso-
lution,whencomparedwithusualcare. Implementationrecom-
mendationsdependonthepreferencesof theAustralianhealth
systemdecisionmakers foreither lowercostorexpeditedclini-
cal resolution.
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